Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34228
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGan, Hui K-
dc.contributor.authorParakh, Sagun-
dc.contributor.authorOsellame, Laura D-
dc.contributor.authorCher, Lawrence M-
dc.contributor.authorUccellini, Anthony-
dc.contributor.authorHafeez, Umbreen-
dc.contributor.authorMenon, Siddharth-
dc.contributor.authorScott, Andrew M-
dc.date2023-
dc.date.accessioned2023-11-15T05:28:08Z-
dc.date.available2023-11-15T05:28:08Z-
dc.date.issued2023-11-13-
dc.identifier.citationExpert Opinion on Biological Therapy 2023; 23(11)en_US
dc.identifier.issn1744-7682-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34228-
dc.description.abstractAntibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the experience with ADCs in brain tumors and examines future paths for their use in these tumors. This review will cover all the key classes of ADCs which have been tested in primary brain tumors, including commentary on the major trials to date. The efficacy of these trials, as well as their limitations, will put in context of the overall landscape of drug development in brain tumors. Importantly, this review will summarize key learnings and insights from these trials that help provide the basis for rationale ways in which these drugs can be effectively and appropriate developed for patients with primary brain tumors. ADC development in brain tumors has occurred in two major phases to date. Key learnings from previous trials provide a strong rationale for the continued development of these drugs for primary brain tumors. However, the unique biology of these tumors requires development strategies specifically tailored to maximize their optimal development.en_US
dc.language.isoeng-
dc.subjectGliomasen_US
dc.subjectantibody drug conjugatesen_US
dc.subjectbiomarkersen_US
dc.subjectblood–brain barrieren_US
dc.titleAntibody drug conjugates for glioblastoma: current progress toward clinical use.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleExpert Opinion on Biological Therapyen_US
dc.identifier.affiliationCancer Therapies and Biology Group, Centre of Research Excellence in Brain Tumours, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.;Tumour Targeting Program, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.;Medical Oncology, Austin Health, Heidelberg, Victoria, Australia.;La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen_US
dc.identifier.affiliationLa Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia.;Department of Biochemistry and Genetics, School of Agriculture, Biomedicine and Environment, La Trobe University, Victoria, Australia.en_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.doi10.1080/14712598.2023.2282729en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37955063-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

56
checked on Nov 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.